BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Farxiga / Forxiga (Dapagliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Farxiga / Forxiga (Dapagliflozin)\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06111443-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT06111
 443)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3.\nStudy: Effect o
 f Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Un
 dergoing Catheter Ablation of Atrial Fibrillation\nEstimated primary compl
 etion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06111443
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954090-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0695409
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: Urinary Proteomics to Guide Early Intervention to Prevent Complica
 tions in Type 2 Diabetes - a Feasibility Study\nEstimated primary completi
 on: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06954090
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311551-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0731155
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: A Comparison of Effectiveness\, Safety\, and Cost-effectiveness of
  Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus
  and High Body Mass Index (BMI)\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0731155
 1
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578520-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0657852
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Heart Failure.\nS
 tudy: Effect of the Use of Dapagliflozin in Patients With Refractory Heart
  Failure\nEstimated primary completion: 1 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06578520
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0722291
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: A Phase IIb Study to Evaluate the Effect of Dapagliflozin i
 n Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in P
 articipants With Chronic Kidney Disease and High Blood Pressure.\nEstimate
 d primary completion: 10 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07222917
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759909-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1 readout est. (NCT0675990
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1.\nStudy: Dapagliflo
 zin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventio
 nal) in Patient with Atrial Fibrillation\nEstimated primary completion: 22
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06759909
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06155604-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0615560
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Ki
 dney Disease\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06155604
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06304857-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630485
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treate
 d with AnthrAcycline - PROTECTAA TRIAL\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06304857
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890143-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0689014
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: The Effica
 cy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disea
 se With Proteinuria in Children\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0689
 0143
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668389-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0666838
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Sodium-Glu
 cose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients 
 for Enhancement of Cardio-Pulmonary Status Trial\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06668389
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595289-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT075952
 89)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na\, Type 2 Diabetes.
 \nStudy: DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagl
 iflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With
  Type 2 Diabetes Mellitus Based on the DP-DCT Platform\nEstimated primary 
 completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07595289
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297589-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0729758
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Epicardial
  Cardiac Fat-CT (EPIC-CT)\nEstimated primary completion: January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07297589
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678203-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1/2 readout est. (NCT07678
 203)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1/2\, Chronic Kidney 
 Disease.\nStudy: Dapagliflozin to Reduce the Decline in Renal Function in 
 Patients Newly Diagnosed With Lupus Nephritis\nEstimated primary completio
 n: 28 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 apagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07678203
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762964-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0676296
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Heart Failure.\nS
 tudy: CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06762964
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868797-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT068687
 97)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na\, Heart Failure.\n
 Study: Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failur
 e Patients on Heart Transplant Waiting List\nEstimated primary completion:
  28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 pagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06868797
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02969798-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT029697
 98)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na\, Type 2 Diabetes.
 \nStudy: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and I
 mpaired Glucose Tolerance (IGT)\nEstimated primary completion: 28 February
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0296
 9798
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06420167-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0642016
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: DapagliFLO
 zin in Renal AL Amyloidosis (FLORAL)\nEstimated primary completion: April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06420
 167
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05174052-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0517405
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Dapagliflo
 zin in Patients With Atrial Fibrillation (DAPA-AF)\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 apagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05174052
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630765
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With Heart Failure and Impaired Kidney Function\nEstimated primary comp
 letion: 16 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06307652
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810998-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07810
 998)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3.\nStudy: Efficacy
  of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome\nEstimated
  primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07810998
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0759886
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD 
 With Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405216-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0740521
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Chronic Kidney Di
 sease.\nStudy: Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhib
 itors in Adolescents With Early Stages of Chronic Kidney Disease\nEstimate
 d primary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07405216
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06610526-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0661052
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Chronic Kidney Di
 sease.\nStudy: A Study of Dapagliflozin in Chinese Adult Patients With Chr
 onic Kidney Disease\nEstimated primary completion: 31 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06610526
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898709-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0789870
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Atherosclerotic C
 ardiovascular Disease.\nStudy: Evaluating SGLT2 Inhibitors for the Reducti
 on of No-Reflow Phenomenon in Patients Undergoing PCI\nEstimated primary c
 ompletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07898709
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174753-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0617475
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Dapagliflo
 zin in STEMI\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06174753
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614230-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0761423
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Periv
 ascular Adipose Tissue in Diabetes\nEstimated primary completion: 1 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076142
 30
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901309-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1/2 readout est. (NCT07901
 309)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1/2.\nStudy: Efficacy
  and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifyi
 ng Antirheumatic Drugs in Patients With Rheumatoid Arthritis\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07901309
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054035-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0605403
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk fo
 r Complications in Subtypes of Patients With Prediabetes\nEstimated primar
 y completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06054035
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351643-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0735164
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Atherosclerotic C
 ardiovascular Disease.\nStudy: CCTA Evaluation of SGLT2i-related Pericoron
 ary Fat Changes Patients With Stage 4 CKM Syndrome\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07351643
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528405-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0652840
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: The Effica
 cy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients Wit
 h Acute Kidney Disease\nEstimated primary completion: July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06528405
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684326-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07684
 326)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3.\nStudy: "Explori
 ng the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Live
 r Disease Patients- A Randomized Controlled Trial"\nEstimated primary comp
 letion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 pagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07684326
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374291-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0537429
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapaglifloz
 in on Renal and Cardiovascular Outcomes in Patients With Severe CKD\nEstim
 ated primary completion: July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05374291
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887062-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0688706
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Dapagliflo
 zin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-
 LVV)\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06887062
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776054-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0777605
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Clinical I
 mpact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpE
 F\nEstimated primary completion: 1 August 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07776054
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944016-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0594401
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney
  Disease in Adolescents and Young Adult Patients\nEstimated primary comple
 tion: September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05944016
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06009874-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT060098
 74)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na.\nStudy: Clinical 
 Investigation of the Cardioprotective Effect of Early Administration of SG
 LT2 in Patients Presented With AMI\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06009
 874
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05938712-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0593871
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: The Effica
 cy\, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glu
 cagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transp
 lant Recipients\nEstimated primary completion: 1 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05938712
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891234-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0789123
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Effect of 
 SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in
  Patients With Insulin Resistance\nEstimated primary completion: 1 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0789
 1234
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778719-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT077787
 19)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na\, Type 2 Diabetes.
 \nStudy: Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD\
 nEstimated primary completion: 10 October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07778719
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096986-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0709698
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Impact of 
 Dapagliflozin for the Regulation of Immunological Activity in Membranous N
 ephropathy\nEstimated primary completion: November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07096986
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848191-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0784819
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Rezdiffra
 ® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adul
 ts With MASH and F2-F3 Fibrosis\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0784819
 1
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436663-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0743666
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Comparativ
 e Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC\nEstimated
  primary completion: 1 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07436663
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05989347-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1 readout est. (NCT0598934
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1.\nStudy: Study to E
 valuate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvan
 t Therapy\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05989347
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174687-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0717468
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: SGLT2 Inhi
 bitors in Geographic Atrophy\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07174687
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07864688-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0786468
 8)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Evaluation
  of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate 
 in Patients With Rheumatoid Arthritis\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapaglifloz
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7864688
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187570-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0718757
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: RECURrence
  of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapa
 gliflozin or Usual Care\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07187570
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392788-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT073927
 88)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na\, Heart Failure.\n
 Study: Early Gliflozin for Elderly Patients With Acute Decompensated Heart
  Failure in the Emergency Department\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 392788
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403955-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT074039
 55)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na\, Heart Failure.\n
 Study: The Effect of Dapagliflozin on Myocardial Strain in Patients With A
 cute Heart Failure\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07403955
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852704-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271204
DTEND;VALUE=DATE:20271205
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0585270
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: SGLT2 Inhi
 bitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Red
 uce Post-opErative AF\nEstimated primary completion: 4 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05852704
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562582-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0656258
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: STunning i
 n Acute Myocardial Infarction - BAS\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflo
 zin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06562582
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469722-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07469
 722)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3\, Heart Failure.\
 nStudy: POcus INTERvention for Tailoring Diuretic Strategy in Acute Decomp
 ensated Heart Failure\nEstimated primary completion: 31 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07469722
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225465-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0722546
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Evaluating
  Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes
  Using Dapagliflozin\nEstimated primary completion: February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07225465
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0626887
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Investigate the Efficacy and Safety of
  Baxdrostat in Combination With Dapagliflozin on CKD Progression in Partic
 ipants With CKD and High Blood Pressure.\nEstimated primary completion: 24
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268873
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239570-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0723957
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Chronic Kidney Di
 sease.\nStudy: A Biomarker-targeted Clinical Trial to Optimize Treatment f
 or Patients With Chronic Kidney Disease\nEstimated primary completion: Jun
 e 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 39570
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235280-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280629
DTEND;VALUE=DATE:20280630
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1 readout est. (NCT0723528
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1.\nStudy: Testing th
 e Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients W
 ith Stage IA Lung Adenocarcinoma\nEstimated primary completion: 29 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0723528
 0
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06907251-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0690725
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Dapagliflo
 zin for Long COVID Syndrome\nEstimated primary completion: 30 June 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06907251
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07482943-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0748294
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Heart Failure.\nS
 tudy: The Effect of Dapagliflozin on Exercise and Cardiac Functional Statu
 s of Patients After Fontan Procedure\nEstimated primary completion: July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074829
 43
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323524-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0732352
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Dapagliflo
 zin in Active Lupus Nephritis\nEstimated primary completion: 1 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07323524
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662044-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0766204
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: A Phase III Study to Investigate the Efficacy and Safety of Elecog
 lipron Alone or in Combination With Dapagliflozin Compared With Placebo in
  Adults With Type 2 Diabetes Mellitus\nEstimated primary completion: 14 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 662044
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785116-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0678511
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: A Randomiz
 ed\, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular R
 isk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)\nE
 stimated primary completion: August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06785116
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491718-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT074917
 18)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na.\nStudy: Manganese
 -enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy\nEstimate
 d primary completion: 9 August 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07491718
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07273838-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0727383
 8)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Heart Failure.\nS
 tudy: Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Car
 diorenal Syndrome\nEstimated primary completion: 31 August 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07273838
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823972-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase na readout est. (NCT078239
 72)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase na.\nStudy: Dapaglifl
 ozin and Right Heart Recovery After ASD Device Closure\nEstimated primary 
 completion: 1 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07823972
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05321706-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0532170
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: DAPAgliflo
 zin for Renal Protection in Heart Transplant Recipients\nEstimated primary
  completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05321706
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140537-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0614053
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Efficacy a
 nd Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovasc
 ular Health in Kidney Transplant Recipients\nEstimated primary completion:
  31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dap
 agliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06140537
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245069-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0724506
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Heart Failure.\nS
 tudy: Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anth
 racycline Chemotherapy in Breast Cancer Patients\nEstimated primary comple
 tion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07245069
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07342764-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0734276
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Dapagliflo
 zin Versus Metformin for the Management of Antipsychotic-Induced Weight Ga
 in: A Pragmatic Pilot Randomized Controlled Trial\nEstimated primary compl
 etion: November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07342764
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741890-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0774189
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Atherosclerotic C
 ardiovascular Disease.\nStudy: aDAPt-ANOCA: Dapagliflozin for the Treatmen
 t of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)\nEstimate
 d primary completion: 1 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07741890
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902726-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0790272
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Type 2 Diabetes.\
 nStudy: Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Ty
 pe 2 Diabetes\nEstimated primary completion: 1 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07902726
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642272-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0664227
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Throug
 h Cluster Randomization Embedded in the Electronic Health Record\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06642272
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516847-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0751684
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Dapagliflo
 zin for Anemia in Lower-Risk Myelodysplastic Syndromes\nEstimated primary 
 completion: January 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07516847
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072326-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0607232
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: dApagliflozin SC0062 and Prevention of Renal Injury\; a Ran
 domized Evaluation\nEstimated primary completion: January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06072326
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025629-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0702562
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Dapagliflozin for Cardio-renal Protection After ICU Discharge\nEstim
 ated primary completion: 15 January 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07025629
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0754787
 8)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: Rapid and Simultaneous Initiation of Four Guideline-Directed CKD T
 herapies (RAPID-CKD)\nEstimated primary completion: 31 March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310433-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0731043
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Dapagliflo
 zin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA i
 n Participants With Metastatic Castrate-resistant Prostate Cancer\nEstimat
 ed primary completion: 30 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07310433
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729592-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0772959
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Dapagliflo
 zin Add-on in Unresectable HCC With Metabolic Syndrome\nEstimated primary 
 completion: July 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07729592
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897500-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0789750
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Dapagliflo
 zin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospe
 ctive\, Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled Trial
 \nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07897500
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539259-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0753925
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Regression
  in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis\nEstimate
 d primary completion: August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07539259
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488689-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0748868
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Assessing 
 the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic S
 hock Patients With Microcirculatory Dysfunction\nEstimated primary complet
 ion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dap
 agliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07488689
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788276-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0578827
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: Can Dapagl
 iflozin Preserve Structure and Function in Transplanted Kidneys?\nEstimate
 d primary completion: August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05788276
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254572-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0725457
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Atherosclerotic C
 ardiovascular Disease.\nStudy: Anti-atherosclerotic Efficacy of Selected A
 ntidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabete
 s\nEstimated primary completion: 1 August 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07254572
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108985-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0710898
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4\, Type 2 Diabetes.\
 nStudy: Effect of Add-on SGLT2i\, TZD\, or Combination Therapy in Type 2 D
 iabetes Patients on DPP4 Inhibitors\nEstimated primary completion: 1 Septe
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflo
 zin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07108985
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0667706
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Phase III Study Investigating Heart Failure and Cardiovascular Death
  With Baxdrostat in Combination With Dapagliflozin\nEstimated primary comp
 letion: 17 December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06677060
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0674272
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Renal Outcomes and Cardiovascular Mortality Stu
 dy to Investigate the Efficacy and Safety of Baxdrostat in Combination Wit
 h Dapagliflozin in Participants With Chronic Kidney Disease and High Blood
  Pressure\nEstimated primary completion: 18 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280585-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20300515
DTEND;VALUE=DATE:20300516
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0728058
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: STOP-PKD: 
 SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease\nEstima
 ted primary completion: 15 May 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07280585
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624305-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0762430
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Evaluate the Effect of Balcinrenone/Da
 pagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)\nEstimated 
 primary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07624305
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364930-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 4 readout est. (NCT0636493
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 4.\nStudy: SGLT2i to 
 Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus\
 nEstimated primary completion: 31 October 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06364930
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923630-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0792363
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2.\nStudy: Validation
  & Intervention Testing for Aging\, Longevity and Healthspan\nEstimated pr
 imary completion: December 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07923630
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05521984-306@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1 readout est. (NCT0552198
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1.\nStudy: Targeting 
 Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Gl
 ucose Cotransporter 2 Inhibitors (SGLT2i)\nEstimated primary completion: 3
 1 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05521984
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
